Engaging diversity in research: does your drug work in overlooked populations?

Karen E. Brown; Erica L. Woodahl

doi:10.1016/B978-0-12-817134-9.00020-9

Engaging diversity in research: does your drug work in overlooked populations?

Karen E. Brown, Erica L. Woodahl

University of Montana

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Underrepresentation among clinical trial participants contributes to evident health disparities and increasing diversity in clinical research is mutually beneficial to patients, providers, and researchers. Clinical trials offers participants critical treatment options, among other benefits, and vast opportunities are found in research-naïve populations. While reasons for this evident disparity in drug development have been documented, sustainable solutions have yet to be implemented. Several initiatives to increase diversity have been introduced by various stakeholders in pharmaceutical research—including changes in regulatory recommendations, engaging different investigators, and innovative partnerships. We developed a long-standing community-academic partnership with an Indigenous population in Montana—the Confederated Salish and Kootenai Tribes—who have largely been underrepresented in research. Our framework has overcome significant barriers and concerns regarding participation in research and can be translated to other overlooked populations. Concerted efforts to support research with diverse populations are required to reduce health inequities and optimize patient care.

Original language	English
Title of host publication	Overcoming Obstacles in Drug Discovery and Development
Subtitle of host publication	Surmounting the Insurmountable-Case Studies for Critical Thinking
Publisher	Elsevier
Pages	283-292
Number of pages	10
ISBN (Electronic)	9780128171349
ISBN (Print)	9780128171349
DOIs	https://doi.org/10.1016/B978-0-12-817134-9.00020-9
State	Published - Jan 1 2023

Publication series

Name	Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking

Keywords

Clinical research
Clinical trials
Community-based participatory research
Diversity
Genetics
Health equity
Inclusion
Participant recruitment
Patient-centricity
Pharmacogenetics
Pharmacogenomics
Rural health
Underserved populations

Access to Document

10.1016/B978-0-12-817134-9.00020-9

Cite this

Brown, K. E., & Woodahl, E. L. (2023). Engaging diversity in research: does your drug work in overlooked populations? In Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking (pp. 283-292). (Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking). Elsevier. https://doi.org/10.1016/B978-0-12-817134-9.00020-9

Brown, Karen E. ; Woodahl, Erica L. / Engaging diversity in research : does your drug work in overlooked populations?. Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking. Elsevier, 2023. pp. 283-292 (Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking).

@inbook{72e22b6c1d7b4df0bd43d270af433c56,

title = "Engaging diversity in research: does your drug work in overlooked populations?",

abstract = "Underrepresentation among clinical trial participants contributes to evident health disparities and increasing diversity in clinical research is mutually beneficial to patients, providers, and researchers. Clinical trials offers participants critical treatment options, among other benefits, and vast opportunities are found in research-na{\"i}ve populations. While reasons for this evident disparity in drug development have been documented, sustainable solutions have yet to be implemented. Several initiatives to increase diversity have been introduced by various stakeholders in pharmaceutical research—including changes in regulatory recommendations, engaging different investigators, and innovative partnerships. We developed a long-standing community-academic partnership with an Indigenous population in Montana—the Confederated Salish and Kootenai Tribes—who have largely been underrepresented in research. Our framework has overcome significant barriers and concerns regarding participation in research and can be translated to other overlooked populations. Concerted efforts to support research with diverse populations are required to reduce health inequities and optimize patient care.",

keywords = "Clinical research, Clinical trials, Community-based participatory research, Diversity, Genetics, Health equity, Inclusion, Participant recruitment, Patient-centricity, Pharmacogenetics, Pharmacogenomics, Rural health, Underserved populations",

author = "Brown, {Karen E.} and Woodahl, {Erica L.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-817134-9.00020-9",

language = "English",

isbn = "9780128171349",

series = "Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking",

publisher = "Elsevier",

pages = "283--292",

booktitle = "Overcoming Obstacles in Drug Discovery and Development",

}

Brown, KE & Woodahl, EL 2023, Engaging diversity in research: does your drug work in overlooked populations? in Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking. Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking, Elsevier, pp. 283-292. https://doi.org/10.1016/B978-0-12-817134-9.00020-9

Engaging diversity in research: does your drug work in overlooked populations? / Brown, Karen E.; Woodahl, Erica L.
Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking. Elsevier, 2023. p. 283-292 (Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Engaging diversity in research

T2 - does your drug work in overlooked populations?

AU - Brown, Karen E.

AU - Woodahl, Erica L.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Underrepresentation among clinical trial participants contributes to evident health disparities and increasing diversity in clinical research is mutually beneficial to patients, providers, and researchers. Clinical trials offers participants critical treatment options, among other benefits, and vast opportunities are found in research-naïve populations. While reasons for this evident disparity in drug development have been documented, sustainable solutions have yet to be implemented. Several initiatives to increase diversity have been introduced by various stakeholders in pharmaceutical research—including changes in regulatory recommendations, engaging different investigators, and innovative partnerships. We developed a long-standing community-academic partnership with an Indigenous population in Montana—the Confederated Salish and Kootenai Tribes—who have largely been underrepresented in research. Our framework has overcome significant barriers and concerns regarding participation in research and can be translated to other overlooked populations. Concerted efforts to support research with diverse populations are required to reduce health inequities and optimize patient care.

AB - Underrepresentation among clinical trial participants contributes to evident health disparities and increasing diversity in clinical research is mutually beneficial to patients, providers, and researchers. Clinical trials offers participants critical treatment options, among other benefits, and vast opportunities are found in research-naïve populations. While reasons for this evident disparity in drug development have been documented, sustainable solutions have yet to be implemented. Several initiatives to increase diversity have been introduced by various stakeholders in pharmaceutical research—including changes in regulatory recommendations, engaging different investigators, and innovative partnerships. We developed a long-standing community-academic partnership with an Indigenous population in Montana—the Confederated Salish and Kootenai Tribes—who have largely been underrepresented in research. Our framework has overcome significant barriers and concerns regarding participation in research and can be translated to other overlooked populations. Concerted efforts to support research with diverse populations are required to reduce health inequities and optimize patient care.

KW - Clinical research

KW - Clinical trials

KW - Community-based participatory research

KW - Diversity

KW - Genetics

KW - Health equity

KW - Inclusion

KW - Participant recruitment

KW - Patient-centricity

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Rural health

KW - Underserved populations

UR - http://www.scopus.com/inward/record.url?scp=85166107643&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/bc4a2ac6-1f33-346e-878a-e2a67f381d91/

U2 - 10.1016/B978-0-12-817134-9.00020-9

DO - 10.1016/B978-0-12-817134-9.00020-9

M3 - Chapter

AN - SCOPUS:85166107643

SN - 9780128171349

T3 - Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking

SP - 283

EP - 292

BT - Overcoming Obstacles in Drug Discovery and Development

PB - Elsevier

ER -

Brown KE, Woodahl EL. Engaging diversity in research: does your drug work in overlooked populations? In Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking. Elsevier. 2023. p. 283-292. (Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking). doi: 10.1016/B978-0-12-817134-9.00020-9

Engaging diversity in research: does your drug work in overlooked populations?

Abstract

Publication series

Keywords

Access to Document

Other files and links

Fingerprint

Cite this